ANIP Stock Analysis: Buy, Sell, or Hold?
ANIP - ANI Pharmaceuticals, Inc.
$81.08
-0.99 (-1.21%)
▼
5d:
-4.67%
30d:
-0.94%
90d:
+3.47%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 14, 2026
30d
Get Alerted When ANIP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ANIP shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: ANIP shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$136.83
Based on 9.1% avg growth
INTRINSIC VALUE TODAY
$84.96
4.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ANIP is currently trading at $81.08, which is considered slightly low relative to its 30-day fair value range of $80.89 to $84.37. The stock's valuation (Forward PE: 7.6) is in line with its historical norms (8.3). Remarkably, the market is currently pricing in an annual earnings decline of 2.9% over the next few years. This pessimistic expectation contrasts with the company's recent 86.1% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ANIP is in a strong uptrend. The price is currently testing key support at $80.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (8th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $112.71 (+39.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ANIP is in a strong uptrend. The price is currently testing key support at $80.05. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (8th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $112.71 (+39.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$80.89 -
$84.37
Company Quality Score
55/100
(HOLD)
Options IV Signal
8th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
83.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 8th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 39.0% below Wall St target ($112.71)
Trading Range Analysis
30-Day Trading Range
$80.89 -
$84.37
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$6.24
(7.7%)
Support & Resistance Levels
Support Level
$80.05
Resistance Level
$87.19
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.58
Wall Street Target
$112.71
(+39.0%)
Revenue Growth (YoY)
20.5%
Earnings Growth (YoY)
86.1%
Profit Margin
10.0%
Valuation Discount vs History
-2.9% cheaper
PE vs Historical
7.6 vs 8.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.9%
(market-implied from PE analysis)
1-Year Target
$78.73
(-3%)
2-Year Target
$76.45
(-6%)
3-Year Target
$74.23
(-9%)
3-Yr Target (if PE normalizes)
(PE: 8→8)
$81.27
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 14.2%)
$346.72
(+328%)
Base:
(SPY PE: 7.6, Growth: 14.2%)
$120.69
(+49%)
Bear:
(PE: 6.4, Growth: 14.2%)
$102.58
(+27%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 20.99 | Current EPS (TTM): $3.91
Bull Case
$180.55
(+123%)
Analyst growth 100.0%, PE expands to 23.1
Base Case
$164.14
(+102%)
Market implied 100.0%, PE stable at 21.0
Bear Case
$55.81
(-31%)
Severe decline -20.0%, PE contracts to 17.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 7.6 to 8.3
Stabilization Target:
$88.77
(+9.5%)
PE Expansion Potential:
+9.5%
Share & Embed Analysis
Last updated: July 14, 2026 3:58 AM ET
Data refreshes hourly during market hours. Next update: 4:58 AM
Data refreshes hourly during market hours. Next update: 4:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ANIP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Meredith Cook
SELL
500 shares
2026-04-13
Meredith Cook
SELL
500 shares
2026-03-13
Christopher Mutz
SELL
3162 shares
2026-03-13
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
Advanced ANIP Option Strategies
Professional options setups generated by AI based on today's ANIP price and gamma walls.